Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

Baird Asset Management controlled Chautauqua Capital Management, a boutique investment firm, released the “Baird Chautauqua ...

Danish drug maker Novo Nordisk has struck partnerships with 10 Indian artificial intelligence (AI) startups to streamline its ...

Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...

In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...

Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

U.S. Sen. Elizabeth Warren has asked the Federal Trade Commission “closely scrutinize” a $16.5 billion deal in which Novo ...

Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.